Tokushima University / Educator and Researcher Directory --- Takata, Haruka

Personal Web Page

https://researchmap.jp/h-takata (researchmap)

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Mazaya Najmina, Shingo Kobayashi, Rena Shimazui, Haruka Takata, Mayuka Shibata, Kenta Ishibashi, Hiroshi Kamizawa, Akihiro Kishimura, Yoshihito Shiota, Daichi Ida, Taro Shimizu, Tatsuhiro Ishida, Yoshiki Katayama, Masaru Tanaka and Takeshi Mori : A Stealthiness Evaluation of Main Chain Carboxybetaine Polymer Modified into Liposome, Pharmaceutics, Vol.16, No.10, 1271, 2024. (Link to Publication Site) ● Publication site (DOI): 10.3390/pharmaceutics16101271 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3390/pharmaceutics16101271 (DOI: 10.3390/pharmaceutics16101271)
2.	Gaballa A Sherif, Taro Shimizu, Haruka Takata, Hidenori ANDO, Ibrahim Mohamed, Emam Emam Abdallah Sherif, Nana Amorim Cristina Matsuo, Yuri Kim, Naguib W Youssef, Mady M Fatma, Khaled A Khaled and Tatsuhiro Ishida : Impact of anti-PEG IgM induced via the topical application of a cosmetic product containing PEG derivatives on the antitumor effects of PEGylated liposomal antitumor drug formulations in mice, Molecular Pharmaceutics, Vol.21, No.2, 622-632, 2024. (Summary) Poly(ethylene glycol) (PEG) is used in many common products, such as cosmetics. PEG, however, is also used to covalently conjugate drug molecules, proteins, or nanocarriers, which is termed PEGylation, to serve as a shield against the natural immune system of the human body. Repeated administration of some PEGylated products, however, is known to induce anti-PEG antibodies. In addition, preexisting anti-PEG antibodies are now being detected in healthy individuals who have never received PEGylated therapeutics. Both treatment-induced and preexisting anti-PEG antibodies alter the pharmacokinetic properties, which can result in a subsequent reduction in the therapeutic efficacy of administered PEGylated therapeutics through the so-called accelerated blood clearance (ABC) phenomenon. Moreover, these anti-PEG antibodies are widely reported to be related to severe hypersensitivity reactions following the administration of PEGylated therapeutics, including COVID-19 vaccines. We recently reported that the topical application of a cosmetic product containing PEG derivatives induced anti-PEG immunoglobulin M (IgM) in a mouse model. Our finding indicates that the PEG derivatives in cosmetic products could be a major cause of the preexistence of anti-PEG antibodies in healthy individuals. In this study, therefore, the pharmacokinetics and therapeutic effects of Doxil (doxorubicin hydrochloride-loaded PEGylated liposomes) and oxaliplatin-loaded PEGylated liposomes (Liposomal l-OHP) were studied in mice. The anti-PEG IgM antibodies induced by the topical application of cosmetic products obviously accelerated the blood clearance of both PEGylated liposomal formulations. Moreover, in C26 tumor-bearing mice, the tumor growth suppressive effects of both Doxil and Liposomal l-OHP were significantly attenuated in the presence of anti-PEG IgM antibodies induced by the topical application of cosmetic products. These results confirm that the topical application of a cosmetic product containing PEG derivatives could produce preexisting anti-PEG antibodies that then affect the therapeutic efficacy of subsequent doses of PEGylated therapeutics. (Keyword) Mice / Humans / Animals / Liposomes / Drug Compounding / COVID-19 Vaccines / Immunoglobulin M / Polyethylene Glycols / Neoplasms / Doxorubicin (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.3c00774 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38273445 ● CiNii @ National Institute of Informatics (CRID): 1360301163936245376 ● Summary page in Scopus @ Elsevier: 2-s2.0-85184304070 (DOI: 10.1021/acs.molpharmaceut.3c00774, PubMed: 38273445, CiNii: 1360301163936245376, Elsevier: Scopus)
3.	Taro Shimizu, Lila S Abu Amr, Yuka Kitayama, Ryo Abe, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Peritoneal B Cells Play a Role in The Production of Anti-Polyethylene Glycol (PEG) IgM Against Intravenously Injected siRNA-PEGylated Liposome Complexes, Biological & Pharmaceutical Bulletin, Vol.47, No.2, 469-477, 2024. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b23-00733 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1248/bpb.b23-00733 (DOI: 10.1248/bpb.b23-00733)
4.	横山宏司, 儘田光和, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : マクロゴール4000の関連する全身性紅斑を呈した女児例, Pediatrics of Japan, Vol.64, No.11, 1196-1199, 2023. (Link to Publication Site) ● Publication site (DOI): 10.18888/sh.0000002763 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390579686915245568 ● Search Scopus @ Elsevier (DOI): 10.18888/sh.0000002763 (DOI: 10.18888/sh.0000002763, CiNii: 1390579686915245568)
5.	Haruka Takata, Taro Shimizu, Rina Yamade, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route, Journal of Controlled Release, Vol.360, 285-292, 2023. (Summary) Modifying the surface of nanoparticles with polyethylene glycol (PEG) is a commonly used approach for improving the in vitro stability of nanoparticles such as liposomes and increasing their circulation half-lives. We have demonstrated that, in certain conditions, an intravenous (i.v.) injection of PEGylated liposomes (PEG-Lip) induced anti-PEG IgM antibodies, which led to rapid clearance of second doses in mice. SARS-CoV-2 vaccines, composed of mRNA-containing PEGylated lipid nanoparticles, have been widely administered as intramuscular (i.m.) injections, so it is important to determine if PEGylated formulations can induce anti-PEG antibodies. If the favorable properties that PEGylation imparts to therapeutic nanoparticles are to be widely applicable this should apply to various routes of administration. However, there are few reports on the effect of different administration routes on the in vivo production of anti-PEG IgM. In this study, we investigated anti-PEG IgM production in mice following i.m., intraperitoneal (i.p.) and subcutaneous (s.c.) administration of PEG-Lip. PEG-Lip appeared to induce anti-PEG IgM by all the tested routes of administration, although the lipid dose causing maximum responses varied. Splenectomy attenuated the anti-PEG IgM production for all routes of administration, suggesting that splenic immune cells may have contributed to anti-PEG IgM production. Interestingly, in vitro experiments indicated that not only splenic cells but also cells in the peritoneal cavity induced anti-PEG IgM following incubation with PEG-Lip. These observations confirm previous experiments that have shown that measurable amounts of PEG-Lip administered i.p., i.m. or s.c. are absorbed to some extent into the blood circulation, where they can be distributed to the spleen and/or peritoneal cavity, and are recognized by B cells, triggering anti-PEG IgM production. The results obtained in this study have important implications for developing efficient PEGylated nanoparticular delivery system. (Keyword) Mice / Animals / Humans / Polyethylene Glycols / Liposomes / COVID-19 Vaccines / Immunoglobulin M / COVID-19 / SARS-CoV-2 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2023.06.027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37355210 ● Search Scopus @ Elsevier (PMID): 37355210 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jconrel.2023.06.027 (DOI: 10.1016/j.jconrel.2023.06.027, PubMed: 37355210)
6.	Emam Emam Abdallah Sherif, Elhewan Emam Elsadek Emam Ali Nehal, Lila Selim Ahmed Ali Abu Amr, Haruka Takata, Yoshino Kawaguchi, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice, Journal of Controlled Release, Vol.334, 327-334, 2021. (Summary) Recently, there is an increasing interest in exosomes or extracellular vesicles as potential candidates for delivering RNAs, proteins, genes, and anticancer agents. Engineering of exosome properties is rapidly evolving as a means of expanding exosome applications. PEGylation of exosomes is a technique used to improve their in vivo stability, circulation half-lives, and sometimes to allow the binding targeting ligands to the exosome exterior. According to FDA guidelines for the development of PEGylated proteins, immunological responses to PEGylated molecules and particles should be examined. In this study, we prepared PEGylated exosomes and investigated the production of anti-PEG IgM antibodies after single i.v. injections in mice. In addition, we monitored blood concentrations and tumor accumulation of a second dose of PEGylated exosomes administered after the initial dose. Single injections of PEGylated exosomes in mice induced anti-PEG IgM production in a T cell-dependent manner. The anti-PEG IgM production decreased when the injection dose of PEGylated exosomes was further increased. Anti-PEG IgM induced by injection of PEGylated exosomes decreased blood concentrations of a second dose of PEGylated exosomes and suppressed their tumor accumulation in a C26 murine colorectal cancer model. Initial injection doses of either PEGylated liposomes or PEGylated ovalbumin (PEG-OVA), both of them induced anti-PEG IgM production, also decreased the blood concentration of PEGylated exosomes. Interestingly, anti-PEG IgM induced by injection of PEGylated exosomes did not affect the blood concentration of PEG-OVA. These results imply the importance of monitoring anti-PEG IgM when repeat PEGylated exosome doses are required and/or when PEGylated exosomes are used together with other PEGylated therapeutics. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2021.05.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33957196 ● Summary page in Scopus @ Elsevier: 2-s2.0-85105280797 (DOI: 10.1016/j.jconrel.2021.05.001, PubMed: 33957196, Elsevier: Scopus)
7.	Milad Reda Qelliny, Taro Shimizu, Nehal Ali Emam Elsadek Emam Elhewan, Sherif Abdallah Emam Emam, Haruka Takata, Zeinab M. A. Fathalla, Amal K. Hussein, Khaled A. Khaled, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Incorporating gangliosides into PEGylated cationic liposomes that complexed DNA attenuates anti-PEG antibody production, but not anti-DNA antibody production in mice, Molecular Pharmaceutics, Vol.18, No.6, 2406-2415, 2021. (Summary) Gangliosides (glycosphingolipids) reduce antibody production by inhibiting B-cell receptor (BCR) signaling. We have shown that a copresentation of gangliosides and polyethylene glycol (PEG) on the same liposomes suppresses anti-PEG IgM production in mice. In addition, we recently observed that pDNA incorporated in PEGylated cationic liposomes (PCLs) induces anti-DNA IgM, which could be a hurdle to the development of efficient gene delivery systems. Therefore, the focus of this study was to determine if the copresentation of gangliosides and DNA on the same PCL would suppress antibody production against DNA. PCLs including DNA induced both anti-PEG IgM production and anti-DNA IgM production. The extent of anti-PEG and anti-DNA IgM production was likely dependent on the immunogenicity of the complexed DNA. Treatment of clodronate-containing liposomes, which causes a depletion of phagocytic cells, suppressed anti-PEG IgM production from PCLs that did not include DNA but failed to suppress anti-PEG IgM production from PCLs that complexed DNA (PCLD). Both anti-PEG IgM and anti-DNA IgM was induced in T-cell-deficient nude mice as well as in normal mice following treatment with PCLs and PCLD, respectively. These results indicate that phagocytic cells contribute to anti-PEG IgM production but not to anti-DNA IgM production, while T-cells do not contribute to any form of antibody production. The copresentation of gangliosides and DNA significantly reduced anti-PEG IgM production but unfortunately did not reduce anti-DNA IgM production. It appears that the immunosuppressive effect of gangliosides, presumably via the CD22 signaling pathway, is limited only to anti-PEG immunity. (Keyword) Animals / Antibody Formation / Cations / Clodronic Acid / DNA / Gangliosides / Gene Transfer Techniques / Genetic Therapy / Immunoglobulin M / Liposomes / Male / Mice / Phagocytes / Plasmids / Polyethylene Glycols (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.1c00255 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33896187 ● Search Scopus @ Elsevier (PMID): 33896187 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.molpharmaceut.1c00255 (DOI: 10.1021/acs.molpharmaceut.1c00255, PubMed: 33896187)
8.	Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Hiro Ueda, Nehal Ali Emam Elsadek Emam Elhewan, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: a possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies, International Journal of Pharmaceutics, Vol.601, 120529, 2021. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2021.120529 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.ijpharm.2021.120529 (DOI: 10.1016/j.ijpharm.2021.120529)
9.	Elhewan Emam Elsadek Emam Ali Nehal, Eri Hondoh, Taro Shimizu, Haruka Takata, Lila Selim Ahmed Ali Abu Amr, Emam Emam Abdallah Sherif, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Impact of pre-existing or induced anti-PEG IgM on the pharmacokinetics of peginterferon alfa-2a (Pegasys®) in mice, Molecular Pharmaceutics, Vol.17, No.8, 2964-2970, 2020. (Summary) PEGylation had been used successfully to improve the circulation half-lives and some physicochemical properties of protein therapeutics. However, anti-polyethylene glycol (anti-PEG) antibodies, either pre-existing or treatment-induced, can negatively affect the pharmacokinetics and pharmacological efficacy of PEGylated proteins. We have examined anti-PEG immune responses in mice for peginterferon alfa-2a (Pegasys), a clinically approved PEGylated protein therapeutic, at both the recommended dose (equivalent to 3 μg/kg in mice) and at higher doses (150 μg/kg) for single or repeated subcutaneous (s.c.) administrations. The effect of treatment-induced anti-PEG IgM on serum concentrations of Pegasys, following repeated administrations, was evaluated. In addition, the effect of pre-existing anti-PEG IgM elicited by a different PEGylated protein, PEG-OVA, on the systemic clearance of Pegasys, was investigated. At a s.c. dose of 3 μg/kg, single injections of Pegasys barely elicited anti-PEG immune responses. Four repeated doses of 150 μg/kg Pegasys elicited anti-PEG IgM production, depending on dose frequency, and triggered the rapid clearance of subsequent doses. In addition, anti-PEG-IgM produced in response to prior administration of PEG-OVA caused a rapid blood clearance of Pegasys. Our results, therefore, underscore the importance of screening for both pre-existing and treatment-induced anti-PEG antibodies in patients prior to and during treatment with PEGylated protein drugs. (Link to Publication Site) ● Publication site (DOI): 10.1021/acs.molpharmaceut.0c00366 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32519877 ● Search Scopus @ Elsevier (PMID): 32519877 ● Search Scopus @ Elsevier (DOI): 10.1021/acs.molpharmaceut.0c00366 (DOI: 10.1021/acs.molpharmaceut.0c00366, PubMed: 32519877)
10.	M Sayed M El, Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Lila Selim Ahmed Ali Abu Amr, Elhewan Emam Elsadek Emam Ali Nehal, E Alaaeldin, Yu Ishima, Hidenori ANDO, A Kamal, A H Sarhan and Tatsuhiro Ishida : Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon, Journal of Controlled Release, Vol.323, 102-109, 2020. (Summary) The accelerated blood clearance (ABC) phenomenon, caused in large degree via in vivo anti-PEG IgM production, is one of obstacles for development of PEGylated liposome and protein formulations, due to decreased efficiency and/or side effects such as anaphylaxis upon repeat administrations. We have shown in murine ABC models that splenectomy suppressed the level of anti-PEG IgM production induced by PEGylated liposomes, indicating that murine splenic B cells play an important role in its production. However, splenectomy did not completely inhibit production of anti-PEG IgM, suggesting that other cells may contribute to its production in the ABC phenomenon. In this study, we examined the contribution of hepatosplenic phagocytic cells to anti-PEG IgM production and clearance of PEGylated liposomes during the ABC phenomenon. Depletion of hepatosplenic phagocytic cells by pretreatment of mice with clodronate-containing non-PEGylated liposomes suppressed anti-PEG IgM production to a considerable degree, without a change in the number of splenic B cells, and attenuated the enhanced clearance of second dose of PEGylated liposomes. These results suggest that hepatosplenic phagocytic cells, in addition to splenic B cells, contribute to the production of anti-PEG IgM and the ABC phenomenon against PEGylated liposomes. The mechanism whereby splenic B cells interact with hepatosplenic phagocytic cells to produce anti-PEG IgM, upon administration of an initial dose of PEGylated liposomes remains to be elucidated. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jconrel.2020.04.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32278827 ● Summary page in Scopus @ Elsevier: 2-s2.0-85083399688 (DOI: 10.1016/j.jconrel.2020.04.011, PubMed: 32278827, Elsevier: Scopus)
11.	Nehal Ali Emam Elsadek Emam Elhewan, Amr Abu Ali Ahmed Selim Lila, Sherif Abdallah Emam Emam, Taro Shimizu, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice, European Journal of Pharmaceutics and Biopharmaceutics, Vol.152, 56-62, 2020. (Summary) Pegfilgrastimis a recombinant PEGylated human granulocyte colony-stimulating factor (G-CSF) analog filgrastim (trade names Neulasta® or G-Lasta®) that stimulates the production of white blood cells (neutrophils). It is employed as an alternative to filgrastim (G-CSF) for chemotherapy-induced neutropenia in patients due to its longer half-life. In clinical settings, PEG-G-CSF is administered to cancer patients via both the s.c. and i.v. routes. In a murine study, we showed that, regardless of administration route, initial doses of PEG-G-CSF above 0.06 mg/kg elicited anti-PEG immune response in a dose-dependent manner. I.v. administration elicited higher levels of anti-PEG IgM than the s.c. route. Initial doses of PEG-G-CSF (6 mg/kg) that were high enough to trigger production of anti-PEG IgM, did not trigger the accelerated clearance of a lower subsequent dose (0.06 mg/kg) that was similar to i.v. clinical doses of PEG-G-CSF, but when the subsequent dose of PEG-G-CSF was raised to (6 mg/kg), the initial dose triggered the accelerated clearance of the second dose via an anti-PEG IgM-mediated complement activation. Similar observations were noted when an increased PEG-OVA dose was given as the second dose, indicating that pre-existing and/or treatment-induced anti-PEG antibodies might compromise the therapeutic activity and/or reduce tolerance of other PEGylated formulations. To the best of our knowledge, this is the first report to suggest the induction of the ABC phenomenon upon repeated injections of pegfilgrastim. In the clinic, cancer patients, receiving multiple cycles of chemotherapy, receive multiple cycles of pegfilgrastim to avoid infections and substantial morbidity. The ABC phenomenon to pegfilgrastim appears to be the cause of loss of clinical benefit of sequential treatments with pegfilgrastim in patients. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejpb.2020.04.026 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32376372 ● Search Scopus @ Elsevier (PMID): 32376372 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejpb.2020.04.026 (DOI: 10.1016/j.ejpb.2020.04.026, PubMed: 32376372)

Review, Commentary:

1.	A Sherif Gaballa, Taro Shimizu, Hidenori ANDO, Haruka Takata, Sherif Abdallah Emam Emam, Eslam Mostafa Ramadan Abdelhameed, W Youssef Naguib, M Fatma Mady, A Khaled Khaled and Tatsuhiro Ishida : Treatment-induced and pre-existing anti-PEG antibodies: Prevalence, clinical implications, and future perspectives, Journal of Pharmaceutical Sciences, Vol.113, No.3, 555-578, Mar. 2024. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.xphs.2023.11.001 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.xphs.2023.11.001 (DOI: 10.1016/j.xphs.2023.11.001)

Proceeding of International Conference:

1.	Shoichiro Fukuda, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto, Hidenori ANDO and Tatsuhiro Ishida : Enhanced effect of ionic liquid on intestinal absorption of macromolecules (< 10 kDa), 39th JSSX and 26th North American ISSX Meeting, Hawaii, Sep. 2024.
2.	Mako Fukumoto, Hidenori ANDO, Reon Kuramoto, Haruka Takata and Tatsuhiro Ishida : A unique immunization method to induce antibodies: intravenous administration of PEGylated exosomes with splenic uptake, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
3.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, Yasukazu Omoto and Tatsuhiro Ishida : Development of a novel human TNF-alpha vaccine formulation: Immunization with inactivated human TNF-alpha variant to induce anti-TNF-alpha antibodies, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
4.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : Ionic liquids improve intestinal absorption of macromolecules of lower molecular weights, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
5.	Matsuo Cristina Amorim Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : Protein-bound cisplatin may increase therapeutic index for cisplatin by reducing its adverse effects, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
6.	Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : A unique spleen-targeted antigen delivery system to obtain antigen-specific antibodies, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
7.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : Effect of anti-PEG IgM on the intramuscular vaccination and pharmacokinetics of mRNA/LNP, CRS 2024 Annual Meeting & Exposition, Bologna, Jul. 2024.
8.	Hitoshi Matsumoto, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : In vivo tumor targeting by NH2-terminated PEG-modified liposomes, Liposome Research Days 2024, Glasgow, Jun. 2024.
9.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Effect of anti-PEG IgM on vaccine efficacy and phrmacokinetics of intramuscuraly administrated PEGylated lipid nanoparticles, Liposome Research Days 2024, Glasgow, Jun. 2024.
10.	Rina Yamade, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : Induction of anti-PEG antibodies by PEGylated liposomes following oral administration, Liposome Research Days 2024, Glasgow, Jun. 2024.
11.	Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : Effect of administration route on the anti-PEG IgM induction by PEGylated liposomes, Liposome Research Days 2024, Glasgow, Jun. 2024.
12.	Haruka Takata, Shunji Abe, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Impact of pre-existing anti-PEG IgM on the mRNA/LNP i.m. vaccination, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
13.	Hitoshi Matsumoto, Haruka Takata, Ayano Sawa-Aihara, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Investigation of therapeutic efficacy of proteasome inhibitor-encapsulated PEG-modified liposomes for UUO-induced renal fibrosis, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
14.	Shoichiro Fukuda, Hidenori ANDO, Chihiro Kato, Haruka Takata, T Nakae, N Tatsumi, H Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 16th International Symposium on Nanomedicine, Osaka, Nov. 2023.
15.	Haruka Takata, Taro Shimizu, Ueda Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : The induction level of anti-PEG IgM by PEGylated liposomes depends on the route of administration and the presence of nucleic acids, 14th International Symposium on Nanomedicine, Nov. 2021.
16.	Taro Shimizu, Haruka Takata, Milad Reda Qelliny and Tatsuhiro Ishida : Evaluation of immunogenicity and adverse effects of nucleic acid-loaded nanoparticles, 14th International Symposium on Nanomedicine, Online, Nov. 2021.
17.	Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : Gene therapy with lipoplexes may worsen inflammation via formation of immune complexes with pre-existing anti-DNA antibodies in SLE-prone mice, Liposome Research Days 2019, Sapporo, Sep. 2019.

Proceeding of Domestic Conference:

1.	Kan Nanako, Hidenori ANDO, Matsuo Nana, Sunami Takaya, Doi Yusuke, Haruka Takata and Tatsuhiro Ishida : ヒトリンパ腫移植マウスにおけるオキサリプラチン封入PEG修飾リポソームとリツキサン併用時における抗腫瘍効果の検討:マクロファージの寄与, 第32回DDSカンファランス, Sep. 2024.
2.	Naruoka Hina, Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : 幼若マウスに腹腔内投与されたPEG修飾リポソームの抗PEG抗体誘導性と脾臓集積性の評価, 第32回DDSカンファランス, Sep. 2024.
3.	Kudo Sotaro, Hidenori ANDO, Kawaguchi Yoshino, Taro Shimizu, Haruka Takata and Tatsuhiro Ishida : 脾臓送達技術を用いて投与したmRNA搭載PEG修飾脂質ナノ粒子の脾臓免疫細胞への移行性とタンパク質発現評価, 第29回創剤フォーラム若手研究会, Sep. 2024.
4.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾脂質ナノ粒子の筋肉内投与による抗PEG抗体誘導への脾臓及びT細胞の寄与, 日本核酸医薬学会第9回年会, Jul. 2024.
5.	Tatsuhiro Ishida, Abe Shunji and Haruka Takata : 抗PEG IgMが及ぼす筋肉内投与型mRNA/LNPワクチンへの影響, 日本核酸医薬学会第9回年会, Jul. 2024.
6.	Tatsuhiro Ishida, Taro Shimizu, Fukuda Shoichiro, Haruka Takata and Hidenori ANDO : イオン液体を用いた中分子化合物の吸収促進技術の開発, 第40回日本DDS学会学術集会, Jul. 2024.
7.	Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : Induction of antigen-specific antibodies by a unique antigen delivery system targeting to spleen, 第40回日本DDS学会学術集会, Jul. 2024.
8.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : Impact of ant-PEG IgM on in vivo performance of PEGylated mRNA/LNP via intramuscularly injection, 第40回日本DDS学会学術集会, Jul. 2024.
9.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : Effect of administration route on the anti-PEG IgM induction by PEGylated nanoparticles, 第40回日本DDS学会学術集会, Jul. 2024.
10.	Mizumachi Kenta, Kawaguchi Yoshino, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 全身性エリテマトーデス(SLE)治療を目指した脾臓辺縁帯B細胞標的化リポソーム開発におけるMRL/lprマウスモデル使用時の課題, 第40回日本DDS学会学術集会, Jul. 2024.
11.	Matsumoto Hitoshi, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾リポソームを用いた新たな腫瘍ターゲティング戦略, 第40回日本DDS学会学術集会, Jul. 2024.
12.	Kim Yuri, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG誘導体含有化粧水の連日皮膚塗布で確認された抗PEG IgM誘導に対する脾臓およびT細胞の関与, 第40回日本DDS学会学術集会, Jul. 2024.
13.	Matsuo Nana, Hidenori ANDO, 田島健次, Haruka Takata, 松島得雄, 草野貴友 and Tatsuhiro Ishida : 細菌由来ナノセルロースの経口摂取による腸内細菌叢調節が食事性肥満モデルマウスの体重増加に与える影響の評価, 第78回日本栄養・食糧学会大会, May 2024.
14.	Matsuo Nana, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : 白金製剤シスプラチンのタンパク結合形が副作用と抗腫瘍効果に与える影響の評価, 日本薬剤学会第39年会, May 2024.
15.	Fukuda Shoichiro, Kato Chihiro, Haruka Takata, 中江崇, 辰巳昇, 濱本英利, Hidenori ANDO and Tatsuhiro Ishida : イオン液体による中分子化合物の経口吸収促進機構の解明に関する検討;消化管上皮タイトジャンクションと化合物の消化管内滞留性への影響, 日本薬剤学会第39年会, May 2024.
16.	Kan Nanako, Hidenori ANDO, Matsuo Nana, Sunami Takaya, Doi Yusuke, Haruka Takata, Masahiro Abe and Tatsuhiro Ishida : ヒト悪性リンパ腫細胞の異種移植モデルに対するオキサリプラチン封入リポソームの単独あるいは抗体医薬との併用における抗腫瘍効果の検討, 日本薬剤学会第39年会, May 2024.
17.	Kim Yuri, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 化粧水塗布による抗PEG IgM誘導メカニズムに関する検討:脾臓およびT細胞の関与, 日本薬剤学会第39年会, May 2024.
18.	Naruoka Hina, Hidenori ANDO, Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : 幼若マウスに対するPEG修飾リポソームの投与による抗PEG抗体誘導の評価, 日本薬剤学会第39年会, May 2024.
19.	Hara Yuto, Hidenori ANDO, Haruka Yamamoto, Haruka Takata, 大本安一 and Tatsuhiro Ishida : キャリアフリーでhTNFαペプチドを免疫して誘導した抗hTNFα抗体の評価と動物種間(マウス・ウサギ)での抗体誘導の比較, 日本薬剤学会第39年会, May 2024.
20.	Haruka Takata, Shunji Abe, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : ポリエチレングリコール(PEG)に対する抗体が及ぼすCOVID-19 mRNAワクチン筋肉内投与後のタンパク質翻訳への影響, 日本薬学会第144年会, Mar. 2024.
21.	Yoshino Kawaguchi, Taro Shimizu, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : B細胞は補体結合リポソームを他の抗原提示細胞へ受け渡す, 日本薬学会第144年会, Mar. 2024.
22.	Mako Fukumoto, Hidenori ANDO, 松島得雄, 草野貴友, Haruka Takata and Tatsuhiro Ishida : 細菌由来ナノセルロースを3D培養基材として用いて調製したエクソソームの有用性検討;エクソソームの分泌特性とタンパク発現の評価, 日本薬学会第144年会, Mar. 2024.
23.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, 大本安一 and Tatsuhiro Ishida : 生体内で抗PD-1抗体を誘導するPD-1ペプチドワクチン開発の基礎的検討:免疫後の抗血清を用いた結合性評価, 日本薬学会第144年会, Mar. 2024.
24.	Nana Matsuo, Hidenori ANDO, Haruka Takata and Tatsuhiro Ishida : CDDPのタンパク結合率制御による副作用軽減と治療効果増強に関する研究:遊離型またはタンパク結合型CDDPが腎臓に与える副作用の評価, 日本薬学会第144年会, Mar. 2024.
25.	Rina Yamade, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 抗PEG抗体誘導にPEG修飾リポソームの投与経路が及ぼす影響, 日本薬学会第144年会, Mar. 2024.
26.	Haruka Takata : PEG修飾ナノ粒子の投与経路が及ぼす抗PEG抗体分泌への影響, 徳島大学大学院医歯薬学研究部DDS研究センター徳島大学研究クラスター「次世代DDS拠点形成」SDGs推進に係る連携創出の場形成支援事業合同シンポジウム, Dec. 2023.
27.	Haruka Yamamoto, Hidenori ANDO, Haruka Takata, 大本安一 and Tatsuhiro Ishida : 新規hTNFαワクチン製剤の開発を目指した不活化hTNFα誘導体のマウスへの免疫と抗体誘導評価, 第2回日本抗体学会学術大会, Dec. 2023.
28.	Mako Fukumoto, Hidenori ANDO, Reon Kuramoto, Haruka Takata and Tatsuhiro Ishida : エクソソームの脾臓免疫による抗体誘導評価:ホスト細胞膜表面に対する結合性評価, 第2回日本抗体学会学術大会, Dec. 2023.
29.	Haruka Takata, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : mRNA/LNPによるタンパク翻訳へ抗PEG IgMが及ぼす影響, 第10回DDS製剤臨床応用FG合宿討論会, Nov. 2023.
30.	Yoshino Kawaguchi, Taro Shimizu, Haruka Takata, Hidenori ANDO and Tatsuhiro Ishida : 補体結合リポソームによる抗原搭載法を利用した新規B細胞ワクチンの開発, 第27回日本ワクチン学会・第64回日本臨床ウイルス学会合同学術集会, Oct. 2023.
31.	Fukuda Shoichiro, Hidenori ANDO, Chihiro Kato, Haruka Takata, 中江崇, 辰巳昇, 濱本英利 and Tatsuhiro Ishida : イオン液体を新規吸収促進剤として用いた中分子化合物の経口吸収改善効果に関する検討, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
32.	Shunto Yamamoto, Hidenori ANDO, Taro Shimizu, Haruka Takata and Tatsuhiro Ishida : 膜タンパク質搭載PEG修飾リポソームの脾臓辺縁帯領域から濾胞領域への送達による膜タンパク質に対する抗体誘導, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
33.	Fukuda Shoichiro, Hidenori ANDO, Chihiro Kato, Haruka Takata, Takashi Nakae, Noboru Tatsumi, Hidetoshi Hamamoto and Tatsuhiro Ishida : The molecular weight limitation on increased intestinal absorption by ionic liquids, 日本薬物動態学会第38回年会, Sep. 2023.
34.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : 筋注後筋組織から血中に漏出した脂質ナノ粒子(LNP)の体内動態に抗PEG IgMが与える影響, 遺伝子・デリバリー研究会第21回夏期セミナー, Aug. 2023.
35.	Rina Yamade, Haruka Takata, Taro Shimizu, Hidenori ANDO and Tatsuhiro Ishida : PEG修飾リポソームの経口投与による抗PEG抗体誘導メカニズムに関する基礎的検討, 第39回日本DDS学会学術集会, Jul. 2023.
36.	Haruka Takata, Taro Shimizu, Shunji Abe, Hidenori ANDO and Tatsuhiro Ishida : デキサメタゾンの事前投与によるmRNA封入PEG修飾脂質ナノ粒子投与時の抗PEG抗体誘導抑制に関する検討, 日本薬剤学会第38年会, May 2023.
37.	Kenta Mizumachi, Taro Shimizu, Hiro Ueda, Haruka Takata, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデスモデルマウス由来B細胞の取り込み能についての検討, 第61回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2022.
38.	Haruka Takata, Taro Shimizu, Shunji Abe, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : デキサメタゾンが及ぼすPEG修飾ナノ粒子による抗PEG抗体誘導への影響, 第16回次世代を担う若手医療薬科学シンポジウム, Oct. 2022.
39.	Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討, 第43回生体膜と薬物の相互作用シンポジウム, Oct. 2022.
40.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 血中の抗PEG抗体が筋肉内投与後のmRNA搭載LNPのタンパク質発現に与える影響に関する検討, 遺伝子・デリバリー研究会第20回夏期セミナー, Aug. 2022.
41.	Haruka Takata, Taro Shimizu, Hiro Ueda, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : siRNA搭載PEG修飾リポソームの投与経路がおよぼす抗PEG抗体誘導への影響に関する検討, 遺伝子・デリバリー研究会第20回夏期セミナー, Aug. 2022.
42.	Shunji Abe, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : mRNA搭載LNP構成成分のPEG脂質が示す免疫原性及びアナフィラキシー様反応への影響, 日本核酸医薬学会第7回年会, Aug. 2022.
43.	Haruka Takata, Hidenori ANDO, 田島健次, Taro Shimizu, Yu Ishima, 松島得雄, 草野貴友 and Tatsuhiro Ishida : ナノフィブリル化バクテリアセルロースを懸濁剤として用いたシクロスポリンA製剤の調製と乾癬治療効果の評価, セルロース学会第29回年次大会, Jul. 2022.
44.	Haruka Takata, Milad Qelliny, Taro Shimizu, Ueda Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ガングリオシドを用いた抗核酸抗体誘導抑制効果の検討, 日本薬剤学会第37年会, May 2022.
45.	Shunji Abe, Haruka Takata, Hidenori ANDO, Taro Shimizu, Yu Ishima and Tatsuhiro Ishida : mRNA封入脂質ナノ粒子構成成分のPEGに対する抗PEG抗体の誘導及びアナフィラキシー様反応への影響, 日本薬剤学会第37年会, May 2022.
46.	Taro Shimizu, Qelliny Milad, Haruka Takata, UEDA Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 核酸搭載PEG修飾カチオン性リポソームによる抗PEG抗体および抗核酸抗体誘導に及ぼすガングリオシド修飾の影響, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
47.	Haruka Takata, Taro Shimizu, Yoshino Kawaguchi, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 投与経路が及ぼすPEG修飾リポソーム投与時の抗PEG抗体誘導に与える影響に関する検討, 第37回日本DDS学会学術集会, Jun. 2021.
48.	Haruka Takata, Milad Reda Qelliny, Taro Shimizu, UEDA Hiro, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : ガングリオシドによるDNA搭載PEG修飾カチオン性リポソーム投与時のPEG及びDNAに対する抗体の産生への影響の検討, 日本核酸医薬学会第6回年会サテライト若手シンポジウム, Jun. 2021.
49.	UEDA Hiro, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデスモデルマウス由来マイクロパーティクルにおけるプロテオーム解析, 日本薬剤学会第36年会, May 2021.
50.	Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 核酸搭載PEG修飾リポソームが全身性エリテマトーデスの発症時期，増悪に与える影響, 日本薬剤学会第36年会, May 2021.
51.	Hiro Ueda, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : 全身性エリテマトーデス病態時の脾臓免疫細胞によるマイクロパーティクルの取り込み変化の検討, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.
52.	Hiro Ueda, Haruka Takata, Taro Shimizu, Hidenori ANDO, Yu Ishima and Tatsuhiro Ishida : マイクロパーティクルによる抗体産生誘導は全身性エリテマトーデスの症状進行に関与する, 第35回日本DDS学会学術集会, Jul. 2019.
53.	Marina Tachibana, Shohei Suenaga, Kohshi Kusumoto, Ryo Sugihara, Haruka Takata, 西辻和親, 辻田麻紀, Tatsuhiro Ishida and Keiichiro Okuhira : 炎症モデルマウスにおけるapoA-I結合タンパク質AIBPの抗炎症作用の検討, 日本薬学会第139年会, Mar. 2019.
54.	Haruka Takata, Taro Shimizu and Tatsuhiro Ishida : Oligonucleotide therapeutics with pDNA/lipoplex would not cause systemic lupus erythematosus but exacerbate systemic lupus erythematosus via formation immune complexes (pDNA/lipoplex-anti DNA antibodies), 第47回日本免疫学会学術集会, Dec. 2018.
55.	Haruka Takata, Yukiyo Kubo, Rie Matsuoka, Taro Shimizu and Tatsuhiro Ishida : pDNA搭載PEG修飾カチオニックリポソーム静脈内投与時の抗二本鎖DNA抗体分泌に関する検討, 第56回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Oct. 2017.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

膜タンパクに対する抗体を誘導するエキソソームの脾臓免疫技術の基盤構築と応用研究 (Project/Area Number: 24K02194 )
人工高分子PEGの皮膚塗布により惹起される抗PEG抗体誘導現象のメカニズム解明 (Project/Area Number: 23K19431 )
イオン液体を用いた中分子医薬品の革新的・非侵襲的吸収促進技術の開発 (Project/Area Number: 23K17477 )
Search by Researcher Number (10986714)

Designated Assistant Professor : Takata, Haruka

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)